Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: CombiGene's CEO on the FDA approval of Hemgenix

Lärkberget

As gene therapies advance through clinical trials, more and more of these treatments are receiving approval from the U.S. Food and Drug Administration and its European counterpart, the European Medicines Agency. The latest in line to gain approval by the FDA was CSL Behring's hemophilia B gene therapy Hemgenix. With a price tag of 3.5 MUSD per dose, Hemgenix will be the most expensive medicine in the world. BioStock reached out to Jan Nilsson, CEO of the Swedish gene therapy company CombiGene, for a comment.

Read the full interview with CombiGene's CEO Jan Nilsson at biostock.se:

https://www.biostock.se/en/2022/12/combigenes-ceo-on-the-fda-approval-of-hemgenix/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.